Regulated information July 10, 2012 TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas ADMIRE CD trial to enroll over 200 patients in 46 centers across 8 countries Leuven (BELGIUM) - July 10, 2012 - TiGenix (NYSE Euronext: TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn`s disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn`s disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn`s disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & … Continue reading →

LEUVEN, BELGIUM--(Marketwire -07/10/12)- TiGenix (EURONEXT:TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn's disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn's disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn's disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & Clinical Development of TiGenix, said: "We are delighted to enrol the first patient in the ADMIRE-CD trial. Hospital Clnic has pioneered the use of stem cell therapies to treat Crohn's disease, and we believe that Cx601 may prove to be a … Continue reading →

REHOVOT, Israel and PARIS, July 9, 2012 /PRNewswire/ -- BioView Ltd. (BIOV.TA) and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit . Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique combination of two innovative technologies, one designed by ScreenCell to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection. "BioView's unique automated imaging and analysis solutions for the detection and of rare cells greatly enhance research and clinical laboratory productivity and assay development process. We are proud to be ScreenCell's global partner and look forward to expanding our relationship." Bioview's Imaging Systems are designed to accommodate both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells. Utilizing field-proven algorithms developed and perfected in collaboration with leading cancer research centers worldwide, BioView's scanning platform is the ideal solution for both clinical and research laboratories wishing to enhance their productivity and assay development processes. ScreenCell offers … Continue reading →

Durham, NC (PRWEB) July 09, 2012 A new study released today in STEM CELLS Translational Medicine shows the potential of a new approach in preparing stem cells that provide relief to people suffering from a common, yet painful diabetes complication. About 70 percent of diabetics have neuropathy, or nerve damage, resulting from the disease, according to the National Institutes of Health. The most common type is peripheral neuropathy (DPN), which causes pain or loss of feeling in the toes, feet, legs, hands and arms. Up to a quarter of DPN sufferers endure an extremely painful version (pDPN) in which even a tiny amount of external pressure can be excruciating. While there are many contributors to DPN, inflammation is considered a major culprit. Treatments are generally restricted to controlling the diabetes itself and to alleviating pain with topical ointments such as capsaicin cream or with oral medications including antidepressants and anticonvulsants. However, none of these therapies directly targets the inflammation, most have negative side effects and less than 30 percent of patients experience adequate pain relief. Clearly, new therapies are needed, said Dr. Ruth Waterman of the Ochsner Clinic Foundation in New Orleans. Dr. Waterman collaborated with Dr. Aline Betancourt from … Continue reading →